COMP <GO>
AMPH vs UNH // GROSS PROFIT MARGIN
Amphastar Pharmaceuticals Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: AMPH 6
— UNH 6
▲ GROSS PROFIT MARGIN LEADER: UNH
LAST: $26.93 (+2.28%) • MKT CAP: $1.15B
gross-margins
49.50%
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
gross-margins
88.57%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AMPH VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AMPH | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 49.50% | 88.57% | -39.07 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.00% | 11.47% | -2.47 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 9.4x | 16.4x | -7.05 | AMPH | /valuation <GO> |
| Free Cash Flow Yield | 10.58% | 6.48% | +4.10 | AMPH | /fcf-yield <GO> |
| Operating Margin | 19.50% | 4.82% | +14.68 | AMPH | /operating-margins <GO> |
| Net Profit Margin | 13.60% | 3.14% | +10.46 | AMPH | /net-margins <GO> |
| Revenue Growth (YoY) | -1.70% | 6.46% | -8.16 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.47 | 3.12 | -0.65 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.8 | 59.2 | +7.64 | AMPH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.9x | 17.1x | -6.19 | AMPH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.15B | $368.83B | -$367.69B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AMPH REV | UNH REV | AMPH GROSS % | UNH GROSS % | AMPH FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $719.9M | $447.57B | 49.5% | 88.7% | $121.2M | $16.07B |
| FY 2024 | $732.0M | $400.28B | 51.1% | 88.3% | $172.3M | $20.70B |
| FY 2023 | $644.4M | $371.62B | — | 89.6% | $183.5M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AMPH // BETA —
UNH // BETA 0.33